Published in Cancer J on March 28, 2012
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175
Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. J Invest Dermatol (2015) 2.18
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol (2013) 1.02
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep (2014) 1.01
Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol (2013) 0.92
The evolution of S100B inhibitors for the treatment of malignant melanoma. Future Med Chem (2013) 0.91
Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun (2015) 0.90
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One (2013) 0.90
A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. BMC Cancer (2014) 0.88
What is new in the treatment of advanced melanoma? State of the art. Contemp Oncol (Pozn) (2012) 0.88
Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep (2015) 0.87
Metastatic melanoma - a review of current and future drugs. Drugs Context (2012) 0.83
Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol (2013) 0.80
The BRAF kinase domain promotes the development of gliomas in vivo. Genes Cancer (2015) 0.79
The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source. Int J Clin Exp Pathol (2012) 0.79
Melanoma m (zero): diagnosis and therapy. ISRN Dermatol (2013) 0.78
The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells. J Biol Chem (2014) 0.77
Intravital fluorescence imaging of small interfering RNA-mediated gene repression in a dual reporter melanoma xenograft model. Nucleic Acid Ther (2012) 0.76
A Microfluidic Device for Multiplex Single-Nucleotide Polymorphism Genotyping. RSC Adv (2013) 0.76
Immunotherapy in the management of melanoma: current status. Immunotargets Ther (2013) 0.75
Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors. Bioorg Med Chem Lett (2013) 0.75
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective. Curr Pharm Des (2016) 0.75
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia. Int J Oncol (2015) 0.75
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Targeted cancer therapy. Nature (2004) 7.81
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res (2010) 4.70
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem (2003) 4.55
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell (2011) 4.02
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med (2010) 3.98
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36
PKB binding proteins. Getting in on the Akt. Cell (2002) 3.34
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80
The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene (2008) 2.66
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Improving melanoma classification by integrating genetic and morphologic features. PLoS Med (2008) 2.52
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res (2010) 2.42
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42
Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res (2009) 2.36
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene (2011) 2.10
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene (2008) 1.79
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am (2009) 1.74
MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res (2010) 1.68
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol (2011) 1.59
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer (2007) 1.57
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene (2010) 1.57
Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell Melanoma Res (2010) 1.55
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res (2007) 1.50
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Cancer Res (2011) 1.46
Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res (2009) 1.44
Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem (1998) 1.40
Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res (2006) 1.34
B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28
Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J Biol Chem (1995) 1.27
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis (2010) 1.25
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res (2009) 1.21
Ipilimumab. Nat Rev Drug Discov (2011) 1.20
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene (2005) 1.20
The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. FEBS Lett (2000) 1.20
Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol (2001) 1.19
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell (2007) 1.15
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene (2011) 1.10
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res (2009) 1.03
Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res (2011) 0.81
Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers. Biochem Pharmacol (2010) 0.81
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol (2010) 0.80
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res (2005) 1.76
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol (2011) 1.59
Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med (2010) 1.47
Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol (2004) 1.42
Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol (2007) 1.41
The role of altered cell-cell communication in melanoma progression. J Mol Histol (2004) 1.34
The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology (2008) 1.34
Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells (2006) 1.27
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl (2011) 1.25
SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells. J Immunol (2010) 1.25
Ipilimumab. Nat Rev Drug Discov (2011) 1.20
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal (2013) 1.19
Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell. J Immunol (2007) 1.17
Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm (2011) 1.17
SHIP limits immunoregulatory capacity in the T-cell compartment. Blood (2009) 1.15
Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res (2013) 1.10
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem Biol (2008) 1.09
SHIP deficiency enhances HSC proliferation and survival but compromises homing and repopulation. Blood (2006) 1.08
Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol (2013) 1.08
Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J Immunol (2006) 1.05
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol Cancer Ther (2008) 0.96
SHIP influences signals from CD48 and MHC class I ligands that regulate NK cell homeostasis, effector function, and repertoire formation. J Immunol (2010) 0.94
Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. Mol Diagn Ther (2009) 0.93
Targeted therapy in melanoma. Clin Dermatol (2013) 0.93
Similar biological activities of two isostructural ruthenium and osmium complexes. Chemistry (2008) 0.92
Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother (2014) 0.90
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One (2013) 0.90
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res (2014) 0.88
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther (2013) 0.88
GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol (2012) 0.87
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res (2014) 0.87
Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget (2011) 0.84
An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance. Cancer Discov (2013) 0.84
Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach. Cancer Res (2013) 0.84
Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP. Eur J Immunol (2012) 0.83
A brief history of melanoma: from mummies to mutations. Melanoma Res (2012) 0.83
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics (2014) 0.82
Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res (2011) 0.81
In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharm (2013) 0.81
Resistance to Raf inhibition in cancer. Drug Discov Today Technol (2014) 0.79
Making sense of MEK1 mutations in intrinsic and acquired BRAF inhibitor resistance. Cancer Discov (2012) 0.78
Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? Expert Rev Anticancer Ther (2011) 0.77
Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines. Methods Enzymol (2010) 0.77
Taming the wild-types: targeting PAK1 in melanomas that lack BRAF mutations. J Natl Cancer Inst (2013) 0.77
Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res (2014) 0.77
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell Melanoma Res (2009) 0.76
Introduction to the Biochemical Pharmacology special issue on targeted cancer therapy. Biochem Pharmacol (2010) 0.75
A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. Melanoma Res (2016) 0.75
Preface: National Cancer Act. Adv Pharmacol (2012) 0.75
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res (2017) 0.75
BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res (2016) 0.75